Welcome to our dedicated page for Pasithea Therapeutics SEC filings (Ticker: KTTAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pasithea Therapeutics Corp. (KTTA, KTTAW) SEC filings page on Stock Titan brings together the company’s official disclosures as a clinical-stage biotechnology issuer listed on The Nasdaq Capital Market. Through documents such as Forms 10-K, 10-Q, 8-K, S-1 and proxy statements, Pasithea reports on its development of PAS-004, a macrocyclic oral MEK inhibitor for NF1-associated plexiform neurofibromas, advanced cancers, ALS and other MAPK pathway-related diseases, as well as on its capital structure and governance decisions.
Current reports on Form 8-K provide timely information on material events, including notices from Nasdaq regarding minimum bid price compliance, changes to at-the-market offering capacity, annual meeting dates and outcomes, and shareholder approvals of items such as stock incentive plan amendments and potential reverse stock splits. These filings help investors understand listing status, financing flexibility and board-authorized corporate actions that may affect KTTA common stock and KTTAW warrants.
Proxy materials and registration statements, such as definitive proxy statements (DEF 14A) and Form S-1 filings, outline proposals submitted to stockholders, including director elections, auditor ratification, equity plan changes and reverse split authorizations, as well as the terms and intended use of proceeds for public offerings. They also describe how Pasithea plans to fund ongoing research, clinical trials and technology development.
On Stock Titan, each new Pasithea filing is captured from EDGAR and paired with AI-powered summaries that explain the key points in accessible language. Users can quickly see what changed in a filing, how it relates to PAS-004 clinical programs, equity offerings, incentive plans or Nasdaq compliance, and then drill down into the full text when deeper review is needed. This structure supports efficient tracking of KTTA and KTTAW regulatory disclosures, from routine reports to significant corporate events.
Pasithea Therapeutics Corp. files its 2025 annual report as a clinical-stage biotech focused on PAS-004, a next-generation macrocyclic MEK 1/2 inhibitor targeting RASopathies, MAPK-driven tumors and NF1-related tumors. The company is running two global Phase 1 programs in advanced cancers and adult NF1 plexiform neurofibromas.
Interim data from the advanced cancer study show no dose-limiting toxicities through eight dose-escalation cohorts and a tolerability profile limited to grade 1–2 treatment-related events, with a PAS-004 half-life of about 60 hours and low peak-to-trough variability. Pasithea also advances discovery program PAS-001 for schizophrenia targeting complement component 4A.
As of June 30, 2025, non-affiliate common stock held a market value of $5.1 million. As of March 24, 2026, there were 24,939,948 common shares outstanding, alongside 64,053,335 pre-funded warrants immediately exercisable at $0.001 per share, subject to beneficial ownership limits.
Pasithea Therapeutics Corp. reports Coastlands-affiliated filers hold 2,394,765 shares, representing 9.99% of common stock. The reported position consists of 1,514,199 shares held directly and 880,566 shares issuable upon exercise of pre-funded warrants, calculated using 23,091,062 shares outstanding as of December 22, 2025. The filing shows shared voting and dispositive power over the 2,394,765 shares and states the 9.99% beneficial ownership limitation applies to the warrants.
The filing is submitted jointly by Coastlands Capital entities and Matthew D. Perry, who is identified as a control person; each reporting person disclaims membership in a group and disclaims beneficial ownership except to the extent of pecuniary interest.
Pasithea Therapeutics Corp. received a notice from Nasdaq on February 20, 2026 stating that its common stock no longer meets the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market.
The company has 180 calendar days, until August 19, 2026, to regain compliance by having its stock close at or above $1.00 per share for at least ten consecutive business days. If it meets other listing standards, it may qualify for an additional 180-day period and could use actions such as a reverse stock split to cure the deficiency.
If compliance is not regained, Nasdaq staff may move to delist the shares, though the company would have the right to appeal. The company plans to monitor its share price and evaluate options, and states that this notice does not affect its business operations or SEC reporting.
Pasithea Therapeutics Corp. received an updated ownership report from institutional investors CVI Investments, Inc. and Heights Capital Management, Inc. The Reporting Persons state beneficial ownership of 899,994 shares of Pasithea common stock, representing 3.8% of the outstanding shares as of the referenced date.
The position consists of shares issuable upon exercise of warrants, which are subject to a 9.99% beneficial ownership limitation that caps how many shares can be acquired at any time. Pasithea’s definitive proxy indicates 23,091,062 shares of common stock were outstanding as of December 22, 2025, providing context for the reported 3.8% stake.
CVI Investments, Inc. is organized in the Cayman Islands and Heights Capital Management, Inc. in Delaware. Heights acts as investment manager to CVI and may exercise voting and dispositive power over the reported shares, while both parties disclaim beneficial ownership beyond their economic interest.
Ameriprise Financial, Inc. and Columbia Management Investment Advisers, LLC filed a Schedule 13G reporting beneficial ownership of 1,930,128 shares of Pasithea Therapeutics Corp. common stock, equal to 8.4% of the class as of 12/31/2025.
Both entities report zero sole voting or dispositive power and shared voting and dispositive power over all reported shares. They state the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Pasithea Therapeutics.
Adage Capital Management, L.P. and related reporting persons report a 2,329,749-share beneficial stake, or 9.99% of Pasithea Therapeutics Corp. common stock. This total includes 229,749 shares issuable upon exercise of warrants held by Adage Capital Partners, L.P.
The stake, tied to an event date of December 31, 2025, is reported as being held in the ordinary course of business and not for the purpose of changing or influencing control of Pasithea. Voting and dispositive power over all reported shares is shared among the reporting persons.
Pasithea Therapeutics Corp. files a Form S-8 to register securities under its 2023 Stock Incentive Plan and incorporates by reference the Form S-8 filed on March 29, 2024. Stockholders approved an amendment to the 2023 Plan at the annual meeting on September 3, 2025. The filing references the company’s Annual Report for the year ended December 31, 2024 and Quarterly Reports for periods ended March 31, 2025 and June 30, 2025, and lists related exhibits and consents, including opinions from Lowenstein Sandler LLP and audit consent from CBIZ CPAs P.C.
Pasithea Therapeutics Corp. reported the results of its 2025 Annual Meeting of Stockholders held on September 3, 2025. Stockholders approved an amendment to the Company’s 2023 Stock Incentive Plan, increasing the shares authorized for issuance by 1,750,000 shares to a total of 2,014,221 shares.
They also elected two Class II directors to terms ending at the 2028 Annual Meeting and ratified CBIZ CPAs P.C. as independent auditor for the fiscal year ending December 31, 2025. In addition, stockholders approved an amendment to the Certificate of Incorporation authorizing the Board, in its discretion, to implement a reverse stock split of the issued common shares at a ratio between 1-for-2 and 1-for-20 at any time before the one-year anniversary of the meeting. A total of 3,495,116 of 7,443,577 shares outstanding were represented, establishing a quorum.
Pasithea Therapeutics Corp. reported condensed interim results showing limited liquidity and continuing operating losses. The company held approximately $7.2 million of cash and reported working capital of about $6.9 million. Management discloses an accumulated deficit of approximately $56.9 million and recurring negative operating cash flows, including net cash used in operating activities of $6.9 million in the recent period. The filing states managements belief that, absent additional financing, there is substantial doubt about the company's ability to continue as a going concern for twelve months from the financial statement date. Capital raises during the period included a May 2025 public offering and related warrant exercises and aggregate gross proceeds of approximately $6.3 million from that offering, proceeds of approximately $4.5 million from a September 2024 private placement, and ATM sales during the six months ended June 30, 2025 generating gross proceeds of approximately $2.08 million. The company continues to depend on equity and/or debt financings to fund operations and development programs.
Pasithea Therapeutics reporting persons CVI Investments, Inc. and Heights Capital Management, Inc. disclose beneficial ownership of 826,145 shares of common stock through Series C and Series D warrants, representing 9.9% of the outstanding class. The Warrants include a contractual limitation that prevents exercise to the extent such exercise would raise ownership above 9.99%. Heights Capital, as investment manager to CVI Investments, may be deemed to have shared voting and dispositive power over the reported position, while neither reporting person claims sole voting or dispositive power. The filing also references 7,443,577 shares outstanding (excluding shares underlying the warrants) as reported in the company's quarterly report.